HC Wainwright & Co. Assigns 'Buy' Rating with $17 Target for Aurinia Pharmaceuticals

HC Wainwright & Co. analyst Arthur He assigned a 'Buy' rating to Aurinia Pharmaceuticals with a $17 target, indicating confidence in the company's future performance. The target price is a new assessment rather than a revision of previous estimates. Based on the one-year price targets, the average target price is $10.14, implying an upside of 13.44% from the current price of $8.94. The estimated GF Value for Aurinia Pharmaceuticals in one year is $14.21, suggesting a 58.95% upside from the current price.

Aurinia Pharmaceuticals Inc. (AUPH) received a positive upgrade from HC Wainwright & Co. analyst Arthur He, who assigned a 'Buy' rating to the stock with a target price of $17. This target price represents a significant increase from the current stock price of $8.94, indicating a potential upside of 13.44% within the next year. The analyst's new assessment suggests a growing confidence in Aurinia's future performance and growth prospects.

The upgrade comes on the heels of recent regulatory approvals and market developments. In June 2025, the FDA approved a 200 mg/mL subcutaneous autoinjector formulation of Benlysta for children ≥ 5 years with active lupus nephritis, enabling at-home administration [1]. Additionally, Roche's Gazyva received FDA acceptance for a supplemental Biologics License Application (sBLA) in March 2025, based on positive Phase III REGENCY results showing a significantly improved complete renal response (CRR) versus standard therapy alone [1].

Technical analysis also provides a mixed outlook for AUPH. While the stock has experienced a recent decrease in price and trading volume, several technical indicators suggest a potential rebound. The Moving Average (MA) trend leans more bullish, with the SMA_20 above the SMA_60, indicating a strong bullish trend. However, the stock has also seen an increase in short selling activity, which may indicate a potential short cover rally [2].

Despite the positive analyst upgrade, AUPH remains within a falling trend, with a total price change of -18.32% over the last 10 days. The stock has experienced fluctuations, ranging from a day low of $8.84 to a day high of $9.19. The estimated GF Value for Aurinia Pharmaceuticals in one year is $14.21, suggesting a 58.95% upside from the current price.

In conclusion, while the stock faces short-term challenges, the recent regulatory approvals and analyst upgrade provide a positive outlook for Aurinia Pharmaceuticals Inc. (AUPH). Investors should closely monitor the stock's performance and technical indicators for further insights into its future trajectory.

References:
[1] https://www.openpr.com/news/4122107/lupus-nephritis-treatment-market-driven-by-biologic-drug
[2] https://intellectia.ai/stock/AUPH/forecast